In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

2016 Dyslipidaemias Pocket Guidelines

Coronary Artery Disease (Chronic)
Cardiovascular Disease in Primary Care
Rehabilitation and Sports Cardiology
Basic Science
Risk Factors and Prevention
Cardiovascular Pharmacotherapy

These Pocket Guidelines deal with the management of dyslipidaemias as an essential and integral part of CVD Prevention.

Chairpersons: Alberico Capatano and Ian Graham

Publication date: 2016

Order Pocket Guidelines


Table of contents

  • Development of the Joint Task Force guidelines
  • What is cardiovascular disease prevention?
    • Definition and rationale
    • Cost-effectiveness of prevention
  • Total cardiovascular risk
    • Total cardiovascular risk estimation
    • Risk levels
  • Evaluation of laboratory lipid and apolipoprotein parameters
    • Fasting or non-fasting?
    • Lipid and lipoprotein analyses
  • Treatment targets
  • Lifestyle modifications to improve the plasma lipid profile
    • The influence of lifestyle on total cholesterol and low-density lipoprotein-cholesterol levels...
    • Lifestyle recommendations to improve the plasma lipid profile
    • Dietary supplements and functional foods for the treatment of dyslipidaemias
    • Other features of a healthy diet contributing to cardiovascular disease prevention
  • Drugs for treatment of hypercholesterolaemia
    • Statins
    • Bile acid sequestrants
    • Cholesterol absorption inhibitors
    • PCSK9 inhibitors
    • Nicotinic acid
  • Triglycerides and cardiovascular disease risk
    • Strategies to control plasma triglycerides
  • High-density lipoprotein-cholesterol and Cardiovascular Risk
  • Management of dyslipidaemia in different clinical settings
    • Familial dyslipidaemias
    • Children
    • Women
    • Older persons
    • Diabetes and metabolic syndrome...
    • Patients with acute coronary syndrome and patients undergoing percutaneous coronary intervention
    • Heart failure and valvular diseases
    • Chronic kidney disease
    • Transplantation.
    • Peripheral arterial disease
    • Stroke
    • Human immunodeficiency virus patients
    • Mental disorders
  • Monitoring of lipids and enzymes in patients on
    lipid-lowering therapy
  • Strategies to encourage adoption of healthy lifestyle changes & adherence to lipid modifying therapies
    • Achieving and adhering to healthy lifestyle changes
    • Adhering to medications